Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE)
Abstract Objectives This subgroup analysis of the MITIGATE study aimed to evaluate whether the efficacy and safety of inebilizumab in Japanese patients with IgG4-related disease are consistent with those observed in the overall trial population. Methods MITIGATE was a randomized…